BioNTech's revenue soared during the COVID era, but the company faces uncertainty with declining vaccine sales and plans for new oncology-focused products.
The company is shifting focus to oncology programs, aiming for multiple late-stage trials and regulatory submissions, and ten indication approvals by 2030.
BioNTech's pipeline includes various oncology drugs targeting different proteins in cancer cells, with potential for 10 indication approvals by 2030.
In this post I provide a whistle-stop tour of the current pipeline and opportunities relative to where the industry is.
I am not especially encouraged, but with COVID funds and management's track record, BioNTech can afford to move at its own pace.
Darwin Brandis/iStock via Getty Images
Investment Overview
BioNTech (NASDAQ:BNTX), the Mainz, Germany based biotech company founded by the husband and wife team Professor Ugur Sahin and Dr. Özlem Türeci, will forever be associated with the COVID pandemic, and the messenger-RNA vaccine against SARS-Cov-2 the company developed alongside the
